Efficacy and safety of olanzapine/fluoxetine combination in the treatment of treatment-resistant depression: a meta-analysis of randomized controlled trials

被引:17
|
作者
Luan, Shuxin [1 ]
Wan, Hongquan [1 ]
Wang, Shijun [1 ]
Li, He [2 ]
Zhang, Baogang [3 ]
机构
[1] Jilin Univ, Hosp 1, Dept Mental Hlth, Changchun, Peoples R China
[2] Jilin Univ, Hosp 1, Dept Pain Med, 71 Xinmin St, Changchun 130021, Jilin, Peoples R China
[3] Jilin Univ, China Japan Union Hosp, Dept Endoscopy, 126 Xiantai St, Changchun 130033, Jilin, Peoples R China
关键词
treatment-resistant depression; olanzapine; fluoxetine; meta-analysis; STAR-ASTERISK-D; ACUTE MANIA; FLUOXETINE; OLANZAPINE; DISORDER; THERAPY; LONG; NORTRIPTYLINE; DEFINITION; OUTCOMES;
D O I
10.2147/NDT.S127453
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Whether olanzapine/fluoxetine combination (OFC) is superior to olanzapine or fluoxetine monotherapy in patients with treatment-resistant depression (TRD) remains controversial. Thus, we conducted this meta-analysis of randomized controlled trials (RCTs) to compare the efficacy and safety of OFC with olanzapine or fluoxetine monotherapy for patients with TRD. Materials and methods: RCTs published in PubMed, Embase, Web of Science, and the ClinicalTrials.gov registry were systematically reviewed to assess the efficacy and safety of OFC. Outcomes included mean changes from baseline in Montgomery-Asberg Depression Rating Scale (MADRS), Clinical Global Impression-Severity (CGI-S), Hamilton Rating Scale for Anxiety (HAM-A), Brief Psychiatric Rating Scale (BPRS) scores, response rate, remission rate, and adverse events. Results were expressed with weighted mean difference (WMD) with 95% confidence intervals (CIs) and risk ratio (RR) with 95% CIs. Results: A total of five RCTs with 3,020 patients met the inclusion criteria and were included in this meta-analysis. Compared with olanzapine or fluoxetine monotherapy, OFC was associated with greater changes from baseline in MADRS (WMD=-3.37, 95% CI: -4.76, -1.99; P < 0.001), HAM-A (WMD=-1.82, 95% CI: -2.25, - 1.40; P < 0.001), CGI-S (WMD=-0.37, 95%CI:-0.45,-0.28;P < 0.001), and BPRS scores (WMD=-1.46, 95% CI: -2.16, -0.76; P < 0.001). Moreover, OFC had significantly higher response rate (RR= 1.35, 95% CI: 1.12, 1.63; P=0.001) and remission rate (RR=1.71, 95% CI: 1.31, 2.23; P < 0.001). The incidence of treatment-related adverse events was similar between the OFC and monotherapy groups (RR= 1.01, 95% CI: 0.94, 1.08; P= 0.834). Conclusion: OFC is more effective than olanzapine or fluoxetine monotherapy in the treatment of patients with TRD. Our results provided supporting evidence for the use of OFC in TRD. However, considering the limitations in this study, more large-scale, well-designed RCTs are needed to confirm these findings.
引用
收藏
页码:609 / 620
页数:12
相关论文
共 50 条
  • [31] Efficacy, safety and tolerability of Symbyax® for acute-phase management of treatment-resistant depression
    Bobo, William V.
    Shelton, Richard C.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2010, 10 (05) : 651 - 670
  • [32] Efficacy and safety of long-term antidepressant treatment for bipolar disorders - A meta-analysis of randomized controlled trials
    Liu, Bangshan
    Zhang, Yan
    Fang, Han
    Liu, Jin
    Liu, Tiebang
    Li, Lingjiang
    JOURNAL OF AFFECTIVE DISORDERS, 2017, 223 : 41 - 48
  • [33] Clozapine Augmentation With Antiepileptic Drugs for Treatment-Resistant Schizophrenia: A Meta-Analysis of Randomized Controlled Trials
    Zheng, Wei
    Xiang, Yu-Tao
    Yang, Xin-Hu
    Xiang, Ying-Qiang
    de Leon, Jose
    JOURNAL OF CLINICAL PSYCHIATRY, 2017, 78 (05) : E498 - +
  • [34] Deep Brain Stimulation in Treatment-Resistant Depression: A Systematic Review and Meta-Analysis on Efficacy and Safety
    Wu, Youliang
    Mo, Jiajie
    Sui, Lisen
    Zhang, Jianguo
    Hu, Wenhan
    Zhang, Chao
    Wang, Yao
    Liu, Chang
    Zhao, Baotian
    Wang, Xiu
    Zhang, Kai
    Xie, Xuemin
    FRONTIERS IN NEUROSCIENCE, 2021, 15
  • [35] Unilateral and bilateral repetitive transcranial magnetic stimulation for treatment-resistant depression: a meta-analysis of randomized controlled trials over 2 decades
    Sehatzadeh, Shayan
    Daskalakis, Zafiris J.
    Yap, Belinda
    Hong-Anh Tu
    Palimaka, Stefan
    Bowen, James M.
    O'Reilly, Daria J.
    JOURNAL OF PSYCHIATRY & NEUROSCIENCE, 2019, 44 (03): : 151 - 163
  • [36] The efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder: a meta-analysis of randomized controlled trials
    Li, Guangjian
    Wang, Xu
    Ma, Dihui
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2016, 12 : 523 - 531
  • [37] Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials
    Jones, Robyn R.
    Freeman, Marlene P.
    Kornstein, Susan G.
    Cooper, Kimberly
    Daly, Ella J.
    Canuso, Carla M.
    Nicholson, Susan
    ARCHIVES OF WOMENS MENTAL HEALTH, 2022, 25 (02) : 313 - 326
  • [38] Efficacy and safety of nitrous oxide for patients with treatment-resistant depression, a randomized controlled trial
    Yan, Danfeng
    Liu, Bangshan
    Wei, Xiyu
    Ou, Wenwen
    Liao, Mei
    Ji, Shanling
    Peng, Yan
    Liu, Jin
    Wu, Shibin
    Wang, Mi
    Ju, Yumeng
    Zhang, Li
    Li, Zexuan
    Li, Lingjiang
    Zhang, Yan
    PSYCHIATRY RESEARCH, 2022, 317
  • [39] Efficacy and safety of ibrexafungerp in the treatment of vulvovaginal candidiasis: A meta-analysis of randomized controlled trials
    He, Rong
    Lin, Fei
    Yu, Bin
    Huang, Ling
    HELIYON, 2024, 10 (08)
  • [40] Clinical efficacy and safety of rimegepant in the treatment of migraine: a meta-analysis of randomized controlled trials
    Wang, Qinghui
    Wang, Shuangmei
    Zhu, Yi
    Lin, Fei
    FRONTIERS IN NEUROLOGY, 2023, 14